查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1733428

全球再生障礙性貧血市場：市場規模（按類型、應用和地區分類）、未來預測

Global Acquired Aplastic Anemia Market Size By Type (Diagnosis and Treatment), By Application (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

後天性再生障礙性貧血市場規模及預測

預計在預測期內（即 2024 年至 2032 年），獲得性再生障礙性貧血市場的收益和市場規模將以顯著的複合年成長率呈指數級成長。

後天性再生障礙性貧血市場規模的成長主要歸因於血液疾病盛行率的增加、資金籌措、醫療保險覆蓋範圍以及血液疾病的意識提升計劃。全球再生障礙性貧血市場報告對市場進行了全面評估。它對關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及在市場中發揮關鍵作用的因素進行了全面的分析。

定義全球再生障礙性貧血市場

後天性再生障礙性貧血是一種罕見的嚴重血液疾病，其特徵是骨髓無法產生血球。骨髓位於骨骼的中心，看起來像海綿狀物質。骨髓負責產生紅血球以及其他血液成分。再生障礙性貧血有兩種：後天性再生障礙性貧血和遺傳性再生障礙性貧血。後天性再生障礙性貧血更為常見，儘管可能是暫時的，但比遺傳性再生障礙性貧血更為罕見。

後天性再生障礙性貧血的病因包括殺蟲劑、砷和苯等毒素、放射和化療以及肝炎、EB病毒巨細胞病毒、細小病毒 B19 和 HIV 等感染疾病。以及狼瘡和類風濕性關節炎等自體免疫疾病。身體其他部位的癌症可能擴散至骨骼並導致後天性再生障礙性貧血。這種疾病主要影響兒童、青少年和年輕人。此疾病的治療方法是支持性的，取決於嚴重程度。

全球再生不良性貧血市場概況

血液疾病盛行率的不斷上升預計將推動全球再生障礙性貧血市場的發展。例如，根據美國疾病管制與美國中心的數據，每 5,000 名男性新生兒中就有 1 名患有A型血友病 A，每年約有 400 名嬰兒出生時患有A型血友病此外，人們對再生障礙性貧血和血液疾病的認知不斷提高可能會推動全球市場的成長。

例如，再生障礙性貧血和骨髓增生異常綜合症國際基金會、NORD-國家罕見疾病組織和 CancerIndex 都在致力於提高人們對再生障礙性貧血的認知。 2019 年 2 月，再生障礙性貧血信託基金會春季宣傳宣傳活動啟動。此外，預測期內政府對研發的支持增加、生活方式的改變以及技術的快速發展預計將推動市場成長。

此外，罕見病患疾病率的上升、對更好治療的需求的增加、對生物技術和製藥行業研發的投資的增加以及資金的可用性正在推動市場的成長。然而，治療成本的上升可能會在預測期內減緩市場成長。治療費用是影響治療方法選擇的主要因素。在美國，一次骨髓移植的費用超過30萬美元。因此，高昂的治療費用可能會阻礙再生障礙性貧血治療市場的成長。

目錄

第 1 章。全球再生障礙性貧血市場：簡介

  • 市場概覽
  • 分析範圍
  • 先決條件

第2章執行摘要

第3章 已驗證的市場研究分析方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章全球再生不良性貧血市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

第5章全球再生不良性貧血市場（按類型）

  • 概述
  • 診斷
  • 治療

6. 全球再生不良性貧血市場（依應用）

  • 概述
  • 醫院
  • 診所
  • 其他

7. 全球再生不良性貧血市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 世界其他地區
    • 拉丁美洲
    • 中東

第8章全球再生不良性貧血市場的競爭格局

  • 概述
  • 各公司市場排名
  • 主要發展策略

第9章 公司簡介

  • Pfizer Inc.
  • Bayer AG
  • Novo Nordisk AS
  • Shire
  • SOBI
  • Octapharma
  • CSL Limited
  • Amgen Inc.
  • GlaxoSmithKline plc.
  • Bluebird bio

第10章 附錄

  • 相關分析
簡介目錄
Product Code: 69301

Acquired Aplastic Anemia Market Size And Forecast

Acquired Aplastic Anemia Market is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecasted period i.e. 2024 to 2032.

The Acquired Aplastic Anemia market size growth is majorly attributed to the increasing prevalence of blood disorders, raising funding, healthcare insurance coverage, and awareness programs for blood disorders. The Global Acquired Aplastic Anemia Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Acquired Aplastic Anemia Market Definition

Acquired Aplastic Anemia is a rare, serious blood disorder, which is characterized by failure of the bone marrow and its inability to produce blood cells. Bone marrow is found in the center of the bones and appears to be like a spongy substance. It is responsible for the production of red blood cells along with other blood components. Aplastic anemia has two manifestations, i.e. Acquired Aplastic Anemia and inherit aplastic anemia Acquired Aplastic Anemia is more common, and sometimes it's only temporary whereas, it is a rare disorder as compared to inherit aplastic anemia.

Various causes of Acquired Aplastic Anemia include toxins, such as pesticides, arsenic, and benzene, radiation and chemotherapy treatments, infectious diseases, such as hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV. And autoimmune disorders, such as lupus and rheumatoid arthritis. Sometimes, cancer from another part of the body can spread to the bone and cause Acquired Aplastic Anemia. The disease occurs mainly in children, teenagers and young adults. The supportive treatments of this disease are available, which depend on the severity of the condition.

Global Acquired Aplastic Anemia Market Overview

An increase in the prevalence of blood disorders is anticipated to drive the global aplastic anemia market. For instance, according to the Centers for Disease Control and Prevention, in the U.S., haemophilia A affects 1 in 5,000 male newborns and about 400 babies are born with haemophilia A each year; an estimated incidence of hemophilia is 1 per 12,000 annually. In addition, an increase in awareness about aplastic anemia and blood disorders is likely to fuel the growth of the global market.

For instance, The Aplastic Anemia and MDS International Foundation, NORD - National Organization for Rare Disorders, Inc., and CancerIndex, among others, are spreading awareness about aplastic anemia. In February 2019, The Aplastic Anemia Trust spring awareness Campaign was launched. Furthermore, increasing government support for research & development, changing lifestyle, and rapidly developing technology is expected to fuel the market growth during the forecast period.

Moreover, the Increasing prevalence of rare diseases, rising demand for better treatment, increasing investment in biotechnology and pharmaceutical industries for R&D, and availability of funds drive the growth of the market. However, the high cost of the treatment may slow the market growth during the period. The cost of treatment is a major factor influencing the selection of the treatment. The cost of a bone marrow transplant is more than US$ 300,000. Thus, the high cost of the treatment is likely to hamper the growth of the aplastic anemia treatment market.

Global Acquired Aplastic Anemia Market: Segmentation Analysis

The Global Acquired Aplastic Anemia Market is segmented based on Type, Application, and Geography.

Acquired Aplastic Anemia Market, By Type

  • Diagnosis
  • Treatment

Based on Type, the market is bifurcated into Diagnosis and Treatment. The Treatment segment is expected to inflate the market growth.

Acquired Aplastic Anemia Market, By Application

  • Hospitals
  • Clinics
  • Others
  • Acquired Aplastic Anemia Market By Application

Based on Application, the market is bifurcated into Hospitals, Clinics, Other. Hospitals are anticipated to become the fastest-growing market in the forecast duration.

Acquired Aplastic Anemia Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of regional analysis, the Global Acquired Aplastic Anemia Market is classified into North America, Europe, Asia Pacific, and Rest of the world. North America dominate the global Acquired Aplastic Anemia market owing to well-developed technology, increasing patient with blood disorders, increasing prevalence of cancer, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Key Players

The "Global Acquired Aplastic Anemia Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Pfizer Inc., Bayer AG, Novo Nordisk AS, Shire, SOBI, Octapharma, CSL Limited, Amgen Inc., GlaxoSmithKline plc., and Bluebird bio. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In June 2021, Heartseed and Novo Nordisk will enter into a global collaboration and licensing agreement for stem cell-based heart failure therapy. Except for Japan, Novo Nordisk will have exclusive rights to develop, manufacture, and commercialize HS-001 internationally. Heartseed will retain the exclusive rights to develop HS-001 in Japan, while Novo Nordisk will co-commercialize the product with Heartseed in Japan on a 50/50 profit and cost-sharing basis.
  • The Food and Drug Administration approved Novartis AG's Promacta as a first-line treatment for aplastic anemia in November 2018.
  • Mergers and Acquisitions
  • Amgen announced on April 16, 2021, that it had completed its previously announced tender offer to buy all outstanding shares of common stock of Five Prime Therapeutics, a clinical-stage biotechnology firm focused on immuno-oncology and targeted cancer medicines, for $38.00 per share in cash. After subtracting relevant transaction fees and expenditures, Amgen will pay approximately $1.9 billion in total consideration to complete the tender offer and subsequent merger.
  • Bayer acquires Asklepios BioPharmaceutical (AskBio) in December 2020 and introduces a new cell and gene therapy platform within the Pharmaceuticals Division. Bayer is now one of the industry's leaders in this rapidly expanding field.
  • In November 2020, Novo Nordisk A/S announced the signing of a formal agreement to acquire Emisphere Technologies Inc. (Emisphere), a drug delivery firm with proprietary technologies, such as the Eligen(R) SNAC technology, that enable therapeutic oral formulations.
  • Product Launches and Product Expansions
  • Promacta, the first-line treatment for aplastic anemia, was approved by the Food and Drug Administration (FDA) in November 2018. Novartis AG introduced it. Novartis AG recently gained permission for Revolade, which is used to treat aplastic anemia in adults.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ACQUIRED APLASTIC ANEMIA MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY TYPE

  • 5.1 Overview
  • 5.2 Diagnosis
  • 5.3 Treatment

6 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Other

7 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East

8 GLOBAL ACQUIRED APLASTIC ANEMIA MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 Pfizer Inc.
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Bayer AG
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Novo Nordisk AS
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Shire
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 SOBI
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Octapharma
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 CSL Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Amgen Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 GlaxoSmithKline plc.
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Bluebird bio
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research